Interferons as Therapeutic Agents in Infectious Diseases by Ferguson, McKenzie C. et al.
Southern Illinois University Edwardsville
SPARK
Pharmacy Faculty Research, Scholarship, and
Creative Activity School of Pharmacy
11-2011
Interferons as Therapeutic Agents in Infectious
Diseases
McKenzie C. Ferguson
Southern Illinois University Edwardsville, mcfergu@siue.edu
Scott Bergman
Southern Illinois University Edwardsville, scbergm@siue.edu
Cathy Santanello
Southern Illinois University Edwardsville, csantan@siue.edu
Follow this and additional works at: http://spark.siue.edu/pharmacy_fac
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the School of Pharmacy at SPARK. It has been accepted for inclusion in Pharmacy Faculty
Research, Scholarship, and Creative Activity by an authorized administrator of SPARK. For more information, please contact gpark@siue.edu.
Recommended Citation
Ferguson, McKenzie C.; Bergman, Scott; and Santanello, Cathy, "Interferons as Therapeutic Agents in Infectious Diseases" (2011).
Pharmacy Faculty Research, Scholarship, and Creative Activity. 3.
http://spark.siue.edu/pharmacy_fac/3
Cover Page Footnote
This is an Accepted Manuscript of an article published by Elsevier in Infectious Disease Clinics of North
America, available at http://dx.doi.org/10.1016/j.idc.2011.07.008
Bergman SJ, Ferguson MC, Santanello C. Interferons as therapeutic agents in infectious diseases. Infect Dis
Clin North Am. 2011;25(4):819-34.
This article is available at SPARK: http://spark.siue.edu/pharmacy_fac/3
 1 
 
Interferons as Therapeutic Agents for Infectious Diseases 
Keywords: Interferon alpha (alfa), viral hepatitis, respiratory tract infection viruses, common cold, 
human papillomavirus, genital warts, vaccine, adjuvant 
 
Scott J. Bergman, PharmD, BCPS* 
Southern Illinois University Edwardsville (SIUE) School of Pharmacy, Department of Pharmacy Practice 
and SIU School of Medicine, Division of Infectious Diseases 
701 N 1
st
 St – Box 19636 
Springfield, IL 62794 
(217) 545-4040 Phone 
(217) 545-8025 Fax 
scbergm@siue.edu 
*Corresponding author 
 
McKenzie Ferguson, PharmD, BCPS 
SIUE School of Pharmacy 
Department of Pharmacy Practice 
220 University Park Dr 
Box 2000 
Edwardsville, IL 62026 
(618) 650-5143 Phone, (618) 650-5141 Fax 
mcfergu@siue.edu  
 
Cathy Santanello, PhD 
SIUE School of Pharmacy 
Department of Pharmaceutical Sciences 
220 University Park Dr 
Box 2000 
Edwardsville, IL 62026 
(618) 650-5165 Phone, Fax (618) 650-5145 
csantan@siue.edu  
 
“The authors have nothing to disclose” 
 2 
 
Synopsis 
 Many attempts have been made to utilize interferons for the treatment or prevention of 
infectious diseases because of their natural antiviral and immunomodulating activity.  This article 
explains the rationale for development of interferons as therapeutic agents and describes commercial 
products available today.  It also provides a summary of studies that have been performed with 
interferons for use as exogenous biological response modifiers in viral infections.  Overall the best data 
exist for treatment of viral hepatitis B and C where interferons are a cornerstone of therapy.  While 
infections with human papillomavirus and common cold viruses sometimes respond favorably to 
interferons, their outcomes are far from ideal.  Finally, the role of interferons as vaccine adjuvants is still 
being explored, but could be promising.      
Introduction 
 Interferons (IFNs) are attractive biological response modifiers for use as therapeutic agents in 
infectious diseases because they have both antiviral and immunomodulatory activity.  Their name even 
comes from the fact that they can “interfere” with viral replication.[1] IFN-α (“leukocyte interferon”) 
and IFN-β (“fibroblast interferon”) are released by human cells infected with certain viruses while IFN-γ 
(“immune interferon”) is produced by natural killer cells (T-cell lymphocytes) in response to antigen 
exposure.  These cytokines then act on uninfected host tissue cells to induce a state of relative 
resistance to viral infections.[2] The agents bind to specific cell-surface receptors that initiate a series of 
intracellular events: induction of certain enzymes, inhibition of cell proliferation, and enhancement of 
immune activities including increased phagocytosis by macrophages and augmentation of specific 
cytotoxicity by T lymphocytes.[3]  Further details on endogenous interferon action and an explanation of 
their activity as biological response modifiers, including in bacterial infections, can be found elsewhere 
in this issue.[4] 
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Even though interferons role against viruses is most prominent, they can also be induced by, 
and active against, rickettsia, mycobacteria and several protozoa.[1]  Therapeutically, however, their use 
has generally been limited to treatment or prevention of viral infections.  Although their potent antiviral 
activity is promising - inhibiting viral replication in vitro at concentrations as low as pg/mL – the 
development of interferons as clinically useful drugs has been largely disappointing.  This can be 
attributed partly to their short half-life in vivo and extensive side effects.  In fact, many symptoms of 
viral infections such as influenza can be blamed on endogenous interferon release.  The adverse effects 
prevalent at therapeutic doses include fever, myalgia, and headache dubbed “flu-like symptoms”, along 
with bone marrow suppression leading to leukocytopenia and thrombocytopenia, plus central nervous 
system manifestations including depression.[1] 
 Interferons have been studied for the treatment or prevention of herpes zoster, herpes simplex, 
and cytomegalovirus infections, but the successful development of acyclovir and ganciclovir gave 
clinicians safer and more effective alternatives for dealing with these viruses.[5, 6] IFNs can also be used 
in the treatment of multiple sclerosis and certain cancers, but this article will review the therapeutic 
applications of interferons for infectious diseases, focusing on viral infections.   
Interferons and IFN-inducers available commercially  
Interferons are not absorbed orally because of their large amino-acid sequence which is 
susceptible to the proteoltyic enzymes in the digestive tract.  However, IFN-α is readily absorbed after 
both intramuscular and subcutaneous injection.[7]  This rapid absorption combined with a short half-life 
means that frequent injections are needed to maintain adequate concentrations in the body.  Both 
commercially available alpha interferon products in the U.S. have now been chemically attached to 
polyethylene glycol (PEG) to enhance their half-life and make once-weekly dosing possible.  This not only 
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makes administration easier, but it also reduces side effects by having a predictably lower peak 
concentration of the exogenous cytokine.   
Both pegylated INFα-2a (Pegasys) and IFNα-2b (PegIntron) are obtained from E. coli by 
recombinant methods.  They consist of naturally occurring small proteins with molecular weights of 
15,000-27,600 daltons.[3]  Each is considered a first-line option for the treatment of chronic hepatitis C 
virus infection in combination with ribavirin.  More details on this use and others will be described later 
in the paper.  Along with the list of additional FDA-approved indications in table 1, IFN-α was shown to 
be an effective treatment for the symptoms of an aggressive case of chronic active Epstein-Barr virus, 
but it did eliminate infection entirely.[8] Therefore additional studies would need to be performed 
before recommendation for this use.   
Human leukocyte derived IFNα-n3 (Alferon N) injection contains a spectrum of alpha interferons 
and is only approved for the treatment of refractory or recurring condylomata acuminata in adult 
patients.  A low dose oral version is in development for use in the treatment and prevention of 
influenza.[9] Both versions have been studied against HIV-1 infection, but with little success.[10, 11] 
Interferon alfacon-1 (Infergen) is considered the synthetic “consensus interferon” because it contains a 
non-natural sequence of IFN-α amino acids all chosen for the highest activity against viral hepatitis.  To 
date, no pegylated formulation of this product has been brought to market.   All the alpha interferons 
include a black box warning in their prescribing information about how their use “may cause or 
aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders.  
Patients should be monitored closely with periodic clinical and laboratory evaluations.  Therapy should 
be withdrawn in patients with persistently severe or worsening signs and symptoms related to side 
effects.  In many, but not all cases, these resolve after stopping therapy.”[12, 13]   
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Interferon-β-1a (Avonex or Rebif) and IFN-β-1b (Betaseron) are recombinant proteins with 166- 
and 165-amino acids respectively.  These beta interferons have antiviral and immunomodulatory 
properties too, but their use at this time is limited to treatment of multiple sclerosis, not infections.  
Interferon-γ-1b (ACTIMMUNE) injection is used regularly for the prevention of infections in patients with 
chronic granulomatous disease along with antibacterials and antifungals.[14]  Its mechanism of action 
for this purpose is not entirely known, but long-term studies show a definite benefit.[15]  Gamma 
interferon can also be used as a salvage therapy for mycobacterial infections, but it is not routinely 
utilized for treatment of this or other infections.[16]           
Topical imiquimod 5% (Aldara) and 3.75% (Zyclara) creams do not have inherent antiviral activity 
alone but instead induce IFN-α, -β and -γ plus tumor necrosis factor (TNF)-α through toll-like receptors.  
Local application to external genital and perianal warts results in an immunomodulatory response that 
stimulates cytokines which have antiviral action and cause a reduction in both viral load and wart 
size.[3]   
Use of interferons for hepatitis viruses 
Chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) affects over 400 million 
people worldwide.[17-19] Chronic viral hepatitis is a leading cause of cirrhosis, liver transplantation and 
hepatocellular carcinoma. With the development of a vaccination series for hepatitis B in the mid-
1980’s, along with increased public education and awareness, acute infection rates of both HBV and HCV 
in the U.S. have declined steadily.[19]  
Hepatitis B virus is a double-stranded DNA virus whereas HCV is a single-stranded RNA virus, 
both of which are capable of significant morbidity and mortality in chronic infection. The exact 
mechanisms of hepatic injury from HBV and HCV infection are not completely understood. Because 
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asymptomatic carriers with normal liver transaminases exist, it is likely multiple immune-mediated 
mechanisms result in hepatocyte damage as opposed to the virus itself being directly cytotoxic.  
Following acute viral infection, the innate immune response initiates formation of natural killer 
(NK) cells, followed by virus-specific CD4+ T cells, and CD8+ cytotoxic T lymphocytes. Natural killer cells 
stimulate production of IFN-α/β and promote cellular clearance of viral proteins through disruption of 
the replication process. Following successful clearance, either spontaneously or by treatment with IFN, 
peripheral cytotoxic T lymphocytes and CD4+ T cell response persists.[20] Chronic infection is likely a 
result of failed innate and adaptive immunity. Specifically, chronic infection with HCV has been 
associated with impaired T cell and NK cell response.[21-24] Genetic factors also likely influence 
progression of disease and predisposition to adverse effects.[25] Though an abundance of research has 
investigated the immune response in relation to chronic viral hepatitis, many areas of uncertainty still 
exist.   
Standard alpha interferon, the first approved IFN for viral hepatitis, lacked several desirable 
pharmacokinetic properties. The addition of PEG created an IFN that has a slower rate of absorption, 
reduced elimination and a longer half-life, necessitating less frequent dosing and fewer adverse effects. 
Furthermore, the PEG moiety results in reduced immunogenicity and sterically hinders the antigenic 
binding site.[26, 27]  Although pegylated IFN has replaced standard IFN-α in treatment of chronic HBV 
and HCV, as many as 40 to 50% of patients still fail to respond to treatment.  Successful response 
depends on many factors including but not limited to viral genotype, viral load and degree of liver 
fibrosis.[25]  
Chronic hepatitis B and C are treated similarly with peginterferon (peg-IFN); however, only 
peginterferon α -2a  is FDA approved in the U.S. for treatment of HBV. Both peg-IFN products are 
administered as subcutaneous injections once weekly for durations up to 48 weeks, dependent upon 
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viral genotype and early viral response for treatment of HCV. Peginterferon α -2b is dosed based on 
body weight (1.5 µg/kg once weekly) whereas peginterferon α -2a is a fixed dose (180 µg/week). 
Ribavirin is used in combination with peg-IFN for treatment of HCV. The exact mechanism of action of 
ribavirin as an adjunctive antiviral agent in HCV is not completely understood.[12, 13] Some studies have 
proposed ribavirin to act as an interferon stimulated gene inducer to improve second phase viral 
decline.[28] Protease inhibitors (boceprevir and telaprevir) are recently approved adjunctive oral agents 
for the treatment of chronic HCV with peg-IFN and ribavirin. To date, all studies of protease inhibitors 
have been conducted in patients with HCV genotype 1, and have shown an increase in sustained 
virologic response (SVR) rates particularly for patients previously unresponsive to IFN therapy.[29-35]. 
The use of IFN for the treatment of chronic HBV and HCV has represented a mainstay of 
treatment for several decades. The specific mechanisms behind the antiviral effects of IFN for hepatitis 
are complex. Interferon stimulated genes are induced by IFN and disrupt viral replication. Hundreds of 
IFN-stimulated genes are thought to exist. Viperin, ISG20 and protein-kinase R (PKR) are just a few of the 
most commonly cited. It is also highly possible that interferon stimulated genes work synergistically to 
produce antiviral activities.[36, 37]  A lack of PKR can lead to an environment conducive to HCV 
replication, though it may not be a good predictor of exogenous IFN response. The study of interferon 
stimulated genes and their role in determining who responds to IFN therapy has been evaluated in 
several studies.[25, 36, 38] Additional studies of interferon stimulated gene expression are needed in 
order to clarify which are directly involved in successful viral response, in what capacity they affect 
response, and if pharmacotherapy directed at induction of interferon stimulated genes can help 
improve treatment response.  
Hepatitis B 
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Chronic HBV infection can be successfully treated with IFN monotherapy.[39]  Loss of viral DNA 
and antibody formation are successful outcomes associated with IFN treatment. The mechanism of IFN 
antiviral activity varies depending on HBeAg-positive or HBeAg-negative disease. In HBeAg-positive 
patients, an immune response is stimulated by IFN whereas in HBeAg-negative disease, IFN acts directly 
as an antiviral.[5] HBeAg-negative disease tends to be more difficult to treat and is associated with a 
longer duration of disease and a higher likelihood of complications such as cirrhosis.[20] A number of 
oral non-nucleoside reverse transcriptase inhibitors are also available for treatment of HBV (entecavir, 
tenofovir, adefovir, lamivudine, and telbivudine).  Although IFN is still considered a first line alternative 
and provides the advantage of defined treatment duration rather than potentially lifelong 
administration, these oral agents are often used in therapy because of their ease of use and reduced 
number of side effects associated with treatment. 
Hepatitis C 
The ability of HCV to evade the host immune response has produced a complex RNA virus 
capable of lingering infection, ultimately resulting in opportunities for increased risk of transmission and 
complications from advanced liver disease. Much of the research regarding the use of IFN for chronic 
viral hepatitis has focused on use in HCV. Following treatment with IFN, a decline in HCV RNA occurs 
over several phases. A rapid inhibition of RNA production within the first 1-2 days of treatment is 
followed by a second, slower phase associated with clearance of infected cells.[23, 40, 41] The immune 
response to endogenous IFN produced by innate immunity and that administered exogenously can differ 
in terms of antiviral activities based on the phase of viral decline.  
Studies have shown that response to IFN based treatment for HCV may be affected by 
differences in IFN signaling and induction. It is likely that HCV has mechanisms to avoid recognition by 
the innate immune response, and as such inhibits the ability of HCV-infected cells to generate IFN.[25, 
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38, 42]  Early studies conducted in non-responders to current therapy showed wide genetic diversity 
with many showing no common traits to predict non-response to IFN therapy.[25, 38, 43]  
However, in 2009, several major studies were published associating a single nucleotide 
polymorphism (SNP) just upstream from interleukin-28B gene (IL28B) with IFN response in patients with 
HCV genotype 1.[44-48] Additional evidence points to the fact that the IL28B polymorphism is also 
linked to spontaneous clearance of HCV.[48, 49] The IL28B variant encodes for IFN-λ3, a type III IFN 
belonging to the IL-10 superfamily, which function in a manner similar to type I IFNs resulting in 
interferon stimulated gene induction.[49-51]  
The genome-wide association study conducted by Ge et al. evaluated over 1600 treatment-
naïve HCV genotype 1 patients, the majority of which originated from the IDEAL study.[45] Results from 
logistic regression showed that the IL28B polymorphism was a stronger predictor of SVR than baseline 
viral load, ethnicity or degree of fibrosis.  Further research in this area is needed to clearly identify a 
future role for genotype testing and further clarify whether it may influence response to therapy in 
other HCV genotypes.  
A multicenter, randomized controlled study by Mangia et al. analyzed 268 Caucasian patients 
with HCV genotype 2 (n=213) and 3 (n=55). Out of 61% of patients that achieved rapid virologic 
response (RVR), IL28B genotype was not associated with SVR, whereas in those patients who did not 
achieve RVR, a significant difference in SVR was noted based on IL28B genotype.[52] At this time, 
genotype testing for IL28B is not routinely recommended for all HCV patients planning to undergo 
treatment, but it may be in the future.  If done, it should not be used as the only factor when choosing a 
treatment strategy.[49]  
Investigational IFN Therapies 
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The complexity of viral defense mechanisms and subsequent effect on the host response has led 
not only to development of chronic infections but also to a lack of a viable vaccine. HCV viral polymerase 
lacks a proofreading capability, creating a more diverse target for vaccine development.[18] Additional 
challenges include the lack of a suitable animal model to mimic a human environment and medium for 
viral growth.[18]  
One of the major limitations to IFN therapy is adverse effects. Malaise, gastrointestinal effects, 
neuropsychiatric effects, neutropenia, and anemia can all limit the effectiveness of treatment by 
necessitating dosage reductions or treatment discontinuation. For newer IFN therapies to be successful, 
they must induce an antiviral response while at the same time limit adverse effects.  
Albinterferon is a new IFN therapy currently in development for the treatment of chronic HCV. 
This product is a combination of interferon α-2b fused to recombinant human albumin. One of the 
advantages with this product is that it only requires once or twice monthly dosing.[53] Not much is 
known at this time about the immunomodulating effects of albinterferon in HCV. It has been shown to 
have similar SVR and adverse event rates to traditional peg-IFN when used in combination with 
ribavirin.[54-56] 
Research into lambda IFN as an agent to treat HCV has also been initiated. It is hypothesized 
that lambda IFNs may be associated with less adverse effects over IFN-α because IFN-λ receptors are 
primarily found in hepatocytes.[49, 57] Specifically, research into new investigational pharmacotherapy 
in the form of pegylated IL-29 (IFN-λ1) in patients with HCV genotype 1 who relapsed following 
traditional treatment with peg-IFN-α and ribavirin appears promising.[50, 57] Both IFN-λ1 and IFN-λ3 
share a common receptor and have a similar sequence identity. [57] 
A four week, open-label study conducted in 56 patients with chronic HCV genotype 1 was 
designed to assess peg-IFN- λ1 in combination with ribavirin.[57] It was a dose escalation study 
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conducted in three parts. Parts 1 and 2 evaluated patients that relapsed following treatment with IFN-α, 
and part 3 included treatment-naïve patients. In part 1, pegylated lambda interferon monotherapy (1.5 
µg/kg or 3 µg/kg) was administered subcutaneously every 2 weeks or weekly. In parts 2 and 3, a range of 
peg-IFN-λ dosages (0.5 µg/kg, 0.75 µg/kg, 1.5 µg/kg or 2.25 µg/kg) were administered weekly in 
combination with ribavirin twice daily (1000 mg for weight < 75 kg and 1200 mg if weight ≥ 75 kg). The 
primary outcomes were safety and tolerability. Pharmacokinetics and viral load reduction were 
evaluated as secondary endpoints.  
Commonly reported adverse effects with PEG IFN-λ included fatigue (29%), nausea (12%), 
myalgia (11%) and headache (9%). Most adverse events were mild or moderate in severity. Four patients 
(7%) experienced treatment-related toxicity and required doses to be withheld. One patient 
experienced grade 3 thrombocytopenic purpura and another patient had elevated ALT, AST and bilirubin 
levels. Both events were considered to be related to treatment with peg-IFN-λ. Aminotransferase 
elevations occurred most often in patients who received high dose (3 µg/kg) PEG IFN-λ monotherapy. 
No clinically relevant decreases in absolute neutrophil count occurred. Also, hemoglobin values 
remained consistent with known effects in patients that received ribavirin therapy. Viral activity 
decreased in the majority of patients that relapsed with previous treatment, with 23 of 24 patients 
achieving at least a > 2-log reduction in HCV RNA. Six of 7 treatment-naïve patients achieved a similar 
reduction in viral load and 2 achieved undetectable HCV RNA levels. Kinetic data showed a linear 
relationship between dose and exposure independent of body weight, which may prompt future 
research into a evaluating a fixed dose of peg-IFN-λ.[57]  
Larger, longer, controlled and blinded studies of lambda IFN as a viable treatment option in HCV 
are needed in order to define its place in therapy and benefits over existing IFN therapy. Studies in other 
HCV genotypes are also needed. Additionally, with the advent of protease inhibitors, more research will 
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be necessary to evaluate how direct antivirals and IL28B genotyping interact in guiding treatment 
decisions. 
Adjunctive therapy with agents that induce or restore interferon stimulated gene expression has 
recently been evaluated in patients with HCV. S-adenosyl methionine (SAMe) given orally was evaluated 
in an open-label study in 24 patients with chronic HCV, genotype 1 who were considered non-
responders to previous IFN and ribavirin treatment.[41] SAMe was administered at a dose of 800 mg 
twice daily in combination with peginterferon alfa-2a (180 µg/kg weekly) and weight-based ribavirin 
(1000 mg for weight < 75 kg and 1200 mg if weight ≥ 75 kg). The primary outcome was change in first 
and second phase viral decline. Treatment response and interferon stimulated gene expression were 
also evaluated after up to 72 weeks of treatment.  Results showed significant improvement in second 
phase viral decline assessed at 2 weeks. Sustained virologic response (SVR) was also evaluated; however, 
this study was not powered to detect differences in virologic response rates. Furthermore, at the time of 
publication, not all patients had reached 24 weeks post-treatment so the full effects on sustained 
virologic response (SVR) were not fully known. The addition of SAMe showed greater induction of 
interferon stimulated genes including, viperin, myxovirus resistance protein and ISG15, compared to 
control.  Adverse effects noted with SAMe were mild and mostly related to gastrointestinal upset, likely 
as a result of lactose in the tablet preparation.[41]  
Additional research is aimed at investigating structure-activity relationships and preliminary 
pharmacokinetic studies into oral IFN inducers that act on TLRs in the treatment of HCV.[58]  
Use of interferons for respiratory virus infection 
 Upper respiratory tract infection in the form of “the common cold” can be caused by a variety of 
viruses including rhinovirus, coronavirus, influenza, parainfluenza, respiratory syncytial virus, 
adenovirus, coxsackie, and echovirus families among others.[59]   Symptoms may include rhinorrhea, 
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nasal obstruction, cough, fever, and sore throat.  The disease is usually mild and self-limited, but a 
number of trials have addressed treatment or prevention of the common cold with therapeutic agents.  
Interferons were once one of the most popular prospects for this purpose, but the little benefit that was 
derived from them was counteracted by the adverse effects inflicted.[60]     
 An early double-blind trial with IFN-α-2b intranasal drops did demonstrate that with use for 
several days prior to experimentally induced rhinovirus infection, common cold symptoms were 
significantly less in study participants compared to placebo drop users.[61] Administration of the drops 
four times daily was superior to a higher dose given once daily at preventing infection.  Short-term use 
was well-tolerated, but obviously it is not realistic for everyone to use intranasal drops four times daily 
throughout the entire cold season.  In an attempt to prevent natural infection during the period of 
increased acute respiratory tract virus activity, a twice daily nasal spray was studied in volunteers over 
28 days.[62]  There was a significant decrease in the number of rhinovirus infections noted, but not in 
any other types of viral respiratory tract infections including parainfluenza.  Adverse events with the 
interferon formulation were quite common in this placebo-controlled trial.  During the first week alone, 
20% of participants receiving interferon spray reported nosebleeds.  This number increased to 41% by 
the end of the study.   
Providing interferon prophylaxis for family members of those infected with common cold viruses 
is a more targeted approach to therapy.  Several studies have addressed the usefulness of IFN nasal 
sprays in this scenario. Seven days of use did significantly reduce rhinovirus infections in two different 
trials when compared to placebo for both individuals (7.9% vs 15.5%) and their families (3.3% vs. 33.3%, 
both p<0.05), but not in two other studies when lower doses were given for a shorter five day course. 
[63-66]   Overall, the intranasal dose of interferon needed to protect against upper respiratory tract 
infection appears to cause significant unwanted effects.[67]  Infection with coronavirus and respiratory 
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syncytial virus has also been an object of investigation for IFN-α-2b nasal sprays, but with little 
success.[68, 69]  A study of intranasal human lymphoblastoid IFN-α-n1 (Wellferon) suggested lower 
prophylactic activity for influenza than it did for rhinovirus.[70] 
 Since results of prophylactic trials with interferons for common cold viruses were not favorable, 
use in the treatment of infection seemed a logical application for this biological response modifier.  
Although some benefit was originally seen with twice daily IFN-α-2b intranasal drops for treatment of 
experimentally induced rhinovirus[71], no advantage was clear when an intranasal spray was used once 
daily for five days to treat natural infection.[72]  Increased rates of blood in the mucus were again noted 
for participants receiving the intervention plus the interferon group experienced more secondary 
complications requiring prescription of antibiotics.  The authors concluded that intranasal interferon was 
ineffective for treating the common cold and it was associated with clinically significant side effects.   
Similar trials with IFN-β-serine and IFN-γ formulations, although initially positive, have shown 
equally disappointing clinical results.[73-76]  Even though the prospects of further study on interferons 
for upper respiratory tract infection appear limited, one modern trial did demonstrate an added benefit 
of intranasal IFNα-2b in combination with an antihistamine (chlorpheniramine) and non-steroidal anti-
inflammatory drug (ibuprofen) at reducing common cold symptoms – showing at least one group is still 
interested in studying the topic.[77]   Investigators have also recently begun research on an alternative 
therapeutic approach for rhinovirus infections using the IFN and TNFα-inducer, imiquimod. Application 
of this intranasal cream in primates has shown promising results in terms of enhancing cytokine 
response, but human trials have not yet been published.[78]     
Use of interferons for genital infections and warts 
 Human papillomoviruses (HPV) are now known to be the cause of cervical cancer and are also 
responsible for genital warts.  They are non-enveloped, double-stranded DNA viruses that invade 
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mucosal and epithelial tissues during sexual contact with an infected partner. It is estimated that over 
50% of the sexually active American population has been or will be infected with HPV at one point in 
their lives.[79]  When hyperproliferation of infected cells occurs, this can lead to genital warts or cancer 
of the cervix, vagina, vulva and penis among others.  There are over 100 different types of HPV and 
approximately 40 of them infect genital mucosa.  Fifteen carcinogenic types of HPV have been 
identified, but two of them are associated with 70% of cervical cancers.[80]  Two vaccines have recently 
been introduced which prevent infection with these most common high-risk types of HPV, 16 and 
18.[81]  One of these vaccines can also induce protection against the most prevalent HPV types that 
have a low-risk of malignancy, but instead cause genital warts - 6 and 11.  
HPV has the ability to persist in stratified epithelia for decades because of mechanisms that 
avoid immune eradication.  Interferon plays a large role in this cycle.[82] Interferons are normally 
secreted by keratinocytes, but HPV reduces their expression. Introduction of low level IFN can actually 
increase early gene transcription and HPV replication which may explain why use of the agent 
therapeutically has had mixed results.[83] Overall outcomes have been positive more often for cases of 
genital warts than reduction of HPV lesions associated with cancers.    A study comparing the in vitro 
activity of IFN-α-2b and IFN-α-n3 on oncogenic HPV 16, 18, and 31b demonstrated that increasing 
concentrations did not always correlate with a stepwise inhibition of HPV replication.[84] Meanwhile, a 
meta-analysis recently analyzed locally-used and systemic interferon for genital warts.[85] Seven 
randomized studies of inferferon intralesional injection or topical gel met criteria for inclusion and 
overall there was a benefit in complete response rates over placebo (44.4% vs. 16.15%, RR 2.68, 95% CI 
1.79 to 4.02).  However there was not a difference in outcomes for trials comparing systemic interferons 
to placebo.  In comparison, clearance of genital and perianal warts occurs in 50% of patients with the 
topical IFN-inducer, imiquimod, usually after 8-10 weeks of use.[3] The 5% imiquimod cream (Aldara®) 
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should be applied to affected areas three times a week for up to 16 weeks while the newer 3.75% cream 
(Zyclara) can be applied once daily for as little as 8 weeks to treat external genital warts caused by HPV.   
 Systemic interferon therapy may be useful when HPV affects areas of the body other than the 
anogenital region.[86]  Successful treatment with systemic PEG IFN-α and a topical retinoid has been 
reported for mucosal carcinomas from epidermodysplasia verruciformis, a genetic abnormality leading 
to persistent and widespread HPV infection of the skin.[87] Recurrent respiratory HPV infection has also 
been effectively treated with IFN-α (12 out of 18 patients), although it had no effect on viral load or 
replication.[88] A 20-year follow-up of patients treated with IFN-α for recurrent respiratory 
papillomatosis confirmed better response rates for HPV-6 than type 11 which had a higher likelihood of 
malignant transformation.[89] For recurrent conjunctival papilloma, topical plus systemic or 
intralesional IFN has been effective with partial excision.[90, 91]  The rapid resolution of significant HPV-
associated warts on the hand, foot and face has also occurred in an HIV-infected patient on 
antiretrovirals while being treated for hepatitis C with PEG IFNα-2b and ribavirin.[92]  
Case reports of treatment with the topical interferon inducer, imiquimod, have shown promise 
for its use in focal epithelial hyperplasia (Heck disease), a rare disorder caused by specific types of HPV 
(13, 14, 32, and 55) affecting oral mucosa primarily in children.[93] In addition to that, imiquimod 5% 
cream has been used successfully in the treatment of plantar warts, a smoother, flatter manifestation of 
HPV 1, 2, and 4 on the foot.[94]  Interestingly the oral H2-antagonist cimetidine, along with reducing 
stomach acid, also induces production of IFN-γ and interleukin-2 which eliminates viral warts in some 
patients.[95] In the future, the improved application of more effective topical interferons may become a 
reality.[96] This could provide a valuable treatment for HPV infections without the systemic side effects 
of current injectable formulations.   
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Use of interferons as vaccine adjuvants 
Adjuvants (adjuvare, Latin for “to help”) are substances that augment the immunogenicity of an 
antigen when mixed with the antigen for use in a vaccine. Adjuvants 1) stimulate granuloma (which is a 
macrophage-rich mass), 2) enhance co-stimulatory signals, 3) stimulate nonspecific lymphocyte 
production, 4) prolong the antigen concentration in a site for lymphocyte exposure [97] and 5) induce 
cytokines [2, 98] 
Research in vaccine development has shown that one of the most promising uses of IFNs is as an 
adjuvant with specific antigens in prophylactic vaccines.[99] Toporovski et al. provides a current review 
of the use of IFN-α, IFN-β, IFN-γ, and IFN- λ in vaccine studies that focus primarily on murine, avian, 
porcine, and non-human species. Regardless of the species, the use of interferons as adjuvants seems to 
improve the efficacy and safety of most vaccines while providing the immunomodulatory effect of 
stimulating the T-helper 1 response.[99] 
In humans, IFN-α, predominantly produced by plasmacytoid dendritic cells, plays a large role in 
the body’s immune response against viruses. [100]  It induces plasma cell differentiation from B-cells, 
causing an increase in the serum level of influenza specific immunoglobulins and channels antigen 
presenting cells (APC’s) to the site of infection.[101] Most research on IFN-α adjuvant activity and its 
subsequent use in approved vaccines seems to indicate that it is a potent adjuvant.[99]  When mixed 
with the influenza vaccine and injected intramuscularly, it is a highly effective adjuvant.[100] 
Oromucosal administration of recombinant IFN-α, like that of natural oromucosal IFN production, has 
been shown to provide immunity against viral infection and tumor cell growth. [102]  Non- or low-
responders to a previous vaccine showed an improved immunoglobulin response with a recombinant 
IFN-α and HBV vaccine.[103] 
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While research is also focused on the other classes of IFNs as adjuvants, thus far they haven’t 
yielded results as promising as that of IFN-α. The use of IFN-β has yielded mixed results; IFN-γ has been 
used primarily in DNA vaccines; even less is known about the use of IFN-λ in vaccines.[99] Nevertheless, 
the use of IFNs as adjuvants shows great promise in augmenting vaccine efficiency and should continue 
to be a top priority in the development of vaccines. 
Conclusion 
Interferons have been tested repeatedly against infectious diseases, but injections are used 
mostly for the treatment of viral hepatitis C and prevention of infections in patients with chronic 
granulomatous disease clinically.  Intralesional IFN and topical inducers are effective for reducing the 
manifestations of genital warts, but they do not eliminate cancer-causing HPV from the body.  IFN has 
not proven to be consistently effective for treatment of respiratory tract infections from the common 
cold or influenza viruses and prophylactic use is not currently feasible.  The severity and quantity of 
adverse effects from systemic IFN therapy make it unattractive for many uses.  Several infections, 
including herpes simplex, herpes zoster, cytomegalovirus and even viral hepatitis B have other effective 
pharmacological treatments.   IFN has been successfully utilized as a vaccine adjuvant and further 
research may allow for additional use of it for that application in the future.   
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 Table 1: Commercially available interferon products 
Product Brand 
names 
FDA-approved indications Usual doses in adults for 
treatment of indicated infections  
Interferon alfa-2a & 
 
 
PEG Interferon α-2a  
injection 
Roferon-A 
 
 
Pegasys 
Chronic HCV, hairy cell leukemia 
and  AIDS-related Kaposi’s 
sarcoma  
Chronic HBV, HCV 
3 million units SC three times 
weekly 
 
180 mcg SC q week x 24 or 48 
weeks  
Interferon alfa-2b & 
 
 
 
 
 
PEG Interferon α-2b  
injection 
Intron A 
 
 
 
 
 
PegIntron, 
Sylatron 
Chronic HBV, chronic HCV, 
condylomata acuminuta, hairy 
cell leukemia, follicular 
lymphoma, and AIDS-related 
Kaposi’s sarcoma 
 
Chronic HCV, melanoma 
3 million units SC three times 
weekly 
 
 
 
 
1.5 mcg/kg  SC q week x 24 or 48 
weeks  
Interferon alfacon 
injection 
 
Infergen Chronic HCV 15 mcg SC daily with ribavirin for 
retreatment of IFN refractory 
disease 
Interferon alfa-n3 
injection 
 
Alferon N Refractory or recurring external 
condylomata acuminata 
Intralesional injection of 250,000 
IU (0.05 mL) per wart twice 
weekly for up to 8 weeks.   
Interferon beta-1a Avonex, Relapsing multiple sclerosis Not indicated for infection 
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injection 
 
Rebif 
Interferon beta-1b 
injection 
Betaseron Relapsing multiple sclerosis Not indicated for infection 
Interferon gamma-1b 
injection 
ACTIMMUNE Reduction in the frequency and 
severity of serious infections 
associated with CGD or 
treatment of severe, malignant 
osteopetrosis 
50 mcg/m
2 
(1 million IU/m
2
) for 
patients whose BSA is greater 
than 0.5m
2 
 SC three times 
weekly 
Imiquimod 5% topical 
cream 
 
Aldara Actinic keratoses of the face or 
scalp, superficial basal cell 
carcinoma, external genital and 
perianal warts/condyloma 
acuminata 
Apply topically three times per 
week until total clearance of 
warts or a maximum of 16 weeks 
Imiquimod 3.75%  
cream 
Zyclara  Actinic keratoses of the full face 
or balding scalp, external genital 
and perianal warts/condyloma 
acuminata 
Apply once daily to the warts 
until total clearance or up to 8 
weeks. 
HBV = Hepatitis B Virus infection, HCV = Hepatitis C Virus Infection, SC = subcutaneously, q= every, AIDS 
= Acquired Immunodeficiency Syndrome, CGD = chronic granulomatous disease, IU = international units, 
BSA = body surface area 
 
